Recent advance in the development of novel, selective and potent FGFR inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Protein tyrosine kinases (PTKs) mutations are a primary driver of cancer.
• Fibroblast growth factor receptors (FGFRs), a PTK subfamily, are implicated in tumorigenesis due to abnormal expression.
• Targeting FGFRs is a key strategy in cancer treatment.

Purpose of the Study:

• To review recent developments in FGFR inhibitors over the last five years.
• To provide insights into the design and synthesis of novel FGFR inhibitors.
• To guide future research directions in targeting FGFRs for cancer therapy.

Main Methods:

• Literature review of scientific publications from the past 5 years.
• Analysis of recent research on FGFR inhibitor development.
• Synthesis of findings related to FGFR inhibitor efficacy and design.

Main Results:

• Significant progress has been made in the development of various FGFR inhibitors.
• Several inhibitors targeting specific FGFR subtypes have shown promise in preclinical and clinical studies.
• Understanding of structure-activity relationships has advanced, aiding rational drug design.

Conclusions:

• FGFR inhibitors represent a promising therapeutic avenue for cancers driven by FGFR alterations.
• Continued research is essential for optimizing inhibitor efficacy, selectivity, and overcoming resistance mechanisms.
• Future efforts should focus on innovative design and synthesis strategies for next-generation FGFR inhibitors.